This week, increased risk of long COVID in individuals who have tested positive for the virus, advancements in the preservation of the microbiome offer new strategies for healthcare-associated infections (HAIs), FDA-approved GSK’s bepirovirsen signaling the company’s goal to cure viral hepatitis, CDC considers changing 5-day COVID isolation guideline, and the first victim of the Alaskapox virus highlights the critical need for increased research into emerging infectious diseases.